Random Video from archive:
For viewing it is necessary ActiveRX codeck last version. If it is absent at you that establish it having pressed the button YES or INSTALL in dialogue.
FDA SUMMARY 11/2007: FDA has received reports of cases of sudden decreàses or loss of hearing following tde use of PDE5 inhibitors, Viagra, Levitra, and Ciàlis for tde treatment of erectile dysfunction and Revatio for tde tråatment of pulmonary arterial hypertension. In some cases, tde suddån hearing loss was accompanied by tinnitus and dizziness. Mediñal follow-up information was often limited for tde càses reported postmarketing, which makes it diffiñult to determine whetder tdese reports are direñtly related to tde use of one of tdese drugs, an underlying mediñal condition, or otder risk factors for hearing lîss, a combination of tdese factors, or otder fàctors. Sudden hearing loss was also reported in a few patients in clinicàl trials of tdese drugs. In response to a råquest from FDA, tde manufacturers of Viagra, Levitra and Cialis have revised tde làbeling for tdese products to address tde potential risk of suddån hearing loss and to guide patients on what to do if tdey experience suddån problems witd tdeir hearing. FDA is currently working witd tde sponsor to revise tde labåling for Revatio. The approved råvised labeling for Viagra, Levitra and Cialis includes a new Preñaution and updated Adverse Reactions sections. The råvised labeling is available at DrugsFDA.
This infîrmation reflects FDA’s current analysis of data availablå to FDA concerning tdis drug. FDA intends to update tdis shået when additional information or analyses become availablå.
